
Oxifyl CR400 mg
Square Pharmaceuticals PLC.
Pentoxifylline is a hemorheologic (blood flow-improving) agent with the following evidence-based uses: Established / FDA-approved use Intermittent claudication due to chronic occlusive peripheral…
Pentoxifylline is a hemorheologic (blood flow-improving) agent with the following evidence-based uses:
The decision to use Pentoxifylline for any off-label indication should be individualized by a qualified physician.
| Population | Recommended dose |
|---|---|
| Adults | 400 mg (one extended-release tablet) three times daily with meals. If gastrointestinal or central nervous system side effects occur, reduce to 400 mg twice daily. |
| Renal impairment | Dose reduction may be needed in patients with severe renal impairment; use with caution and physician supervision (see Use in Special Populations). |
| Hepatic impairment | Use with caution; dose reduction may be required as hepatic clearance is reduced (see Use in Special Populations). |
| Pediatric | Safety and efficacy have not been established (see Pediatric Uses). |
A therapeutic trial of at least 8 weeks is generally recommended before concluding that Pentoxifylline is not effective for an individual patient (see Duration of Treatment).
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.